Document is current

Article History

Received: 24 August 2021

Accepted: 21 February 2022

First Online: 7 April 2022

Declarations

:

: The study protocol was approved by the Oxford Tropical Research Ethics Committee (OxTREC ref no.1030-13) and the Ethics Review Committee at Hospital for Tropical Diseases (CS/ND/14/14). All patients or their legal representatives signed an informed consent form. This research was compliant with the Helsinki Declaration. All personal identifiers did not include in the data for confidentiality.

: Not applicable.

: BW reports receipt of honoraria from Takeda Pharmaceutical Company for membership of the Data Safety Monitoring Committee for their dengue vaccine trials and from Roche for contributions to their Severe Dengue Advisory Board.Drs. Moulton and Mulligan are co-inventors of the CRI algorithm. The underlying intellectual property is assigned to the University of Colorado, which licensed the technology to Flashback Technologies, Inc. Drs. Moulton and Mulligan have equity interests in Flashback Technologies, where Dr. Moulton is the Chief Medical Officer and serves on the Board of Directors. Drs. Moulton and Mulligan receive royalty payments from the University of Colorado. The other authors have declared no conflicts of interest.Development of the CRI algorithm has been supported in part by funding from the US Army Medical Research and Material Command (USAMRMC) under Grant Nos. DM09027, W81XWH-15-2-0007, W81XWH-09-1-0750, W81XWH-09-C-0160, W81XWH-11-2-0091, W81XWH-11-2-0085, W81XWH-12-2-0112, W81XWH-13-C-0121, and W81XWH-15-9-0001. The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless so designated by other documentation.